Benjamin Kearns

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1307551/publications.pdf

Version: 2024-02-01

566801 433756 1,005 35 15 31 citations h-index g-index papers 37 37 37 1701 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Incorporating external trial data to improve survival extrapolations: a pilot study of the COU-AA-301 trial. Health Services and Outcomes Research Methodology, 2022, 22, 317-331.	0.8	4
2	Optimizing the Design of a Repeated Fecal Immunochemical Test Bowel Cancer Screening Programme With a Limited Endoscopy Capacity From a Health Economic Perspective. Value in Health, 2022, 25, 954-964.	0.1	4
3	Dynamic and Flexible Survival Models for Extrapolation of Relative Survival: A Case Study and Simulation Study. Medical Decision Making, 2022, 42, 945-955.	1.2	1
4	Schizophrenia Treatment with Second-Generation Antipsychotics: A Multi-Country Comparison of the Costs of Cardiovascular and Metabolic Adverse Events and Weight Gain. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 125-137.	1.0	12
5	The Extrapolation Performance of Survival Models for Data With a Cure Fraction: A Simulation Study. Value in Health, 2021, 24, 1634-1642.	0.1	12
6	Comparing current and emerging practice models for the extrapolation of survival data: a simulation study and case-study. BMC Medical Research Methodology, 2021, 21, 263.	1.4	12
7	How Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost Effectiveness. Pharmacoeconomics, 2020, 38, 193-204.	1.7	25
8	PMU13 Schizophrenia Treatment with Second-Generation Antipsychotics: A MULTI-Country Evaluation of the Costs of Cardiovascular and Metabolic Adverse Events and Weight GAIN. Value in Health, 2020, 23, S605.	0.1	0
9	External Validation of a Colorectal Cancer Model Against Screening Trial Long-Term Follow-Up Data. Value in Health, 2019, 22, 1154-1161.	0.1	4
10	A Review of Survival Analysis Methods Used in NICE Technology Appraisals of Cancer Treatments: Consistency, Limitations, and Areas for Improvement. Medical Decision Making, 2019, 39, 899-909.	1.2	28
11	Generalized Linear Models for Flexible Parametric Modeling of the Hazard Function. Medical Decision Making, 2019, 39, 867-878.	1.2	24
12	The association between long-term conditions and uptake of population-based screening for colorectal cancer: results from two English cohort studies. Cancer Management and Research, 2018, Volume 10, 637-645.	0.9	6
13	Cost-effectiveness of superficial femoral artery endovascular interventions in the UK and Germany: a modelling study. BMJ Open, 2017, 7, e013460.	0.8	10
14	The cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in England: a model-based economic evaluation. BMC Health Services Research, 2017, 17, 78.	0.9	16
15	Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2017, 35, 415-424.	1.7	7
16	The clinical effectiveness of different surveillance strategies to prevent colorectal cancer in people with intermediate-grade colorectal adenomas: a retrospective cohort analysis, and psychological and economic evaluations. Health Technology Assessment, 2017, 21, 1-536.	1.3	23
17	Factors associated with completion of bowel cancer screening and the potential effects of simplifying the screening test algorithm. British Journal of Cancer, 2016, 114, 327-333.	2.9	7
18	Legacy and Emerging Perfluoroalkyl Substances Are Important Drinking Water Contaminants in the Cape Fear River Watershed of North Carolina. Environmental Science and Technology Letters, 2016, 3, 415-419.	3.9	444

#	Article	IF	Citations
19	Patterns of multimorbidity and their association with health outcomes within Yorkshire, England: baseline results from the Yorkshire Health Study. BMC Public Health, 2016, 16, 649.	1.2	35
20	Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluation. BMC Medicine, 2016, 14, 200.	2.3	23
21	Cohort Profile: The Yorkshire Health Study. International Journal of Epidemiology, 2016, 45, 707-712.	0.9	29
22	Improved identification of people at risk of psychosis: is it value for money?. Lancet Psychiatry,the, 2015, 2, 951-952.	3.7	0
23	Examining the impact of 11 long-standing health conditions on health-related quality of life using the EQ-5D in a general population sample. European Journal of Health Economics, 2015, 16, 141-151.	1.4	62
24	Guaiac faecal occult blood test performance at initial and repeat screens in the English Bowel Cancer Screening Programme. British Journal of Cancer, 2014, 111, 1734-1741.	2.9	16
25	Predicting preference-based utility values using partial proportional odds models. BMC Research Notes, 2014, 7, 438.	0.6	3
26	Enhancements to angioplasty for peripheral arterial occlusive disease: systematic review, cost-effectiveness assessment and expected value of information analysis. Health Technology Assessment, 2014, 18, 1-252.	1.3	26
27	Predicting the prevalence of chronic kidney disease in the English population: a cross-sectional study. BMC Nephrology, 2013, 14, 49.	0.8	31
28	Innovation in health economic modelling of service improvements for longer-term depression: demonstration in a local health community. BMC Health Services Research, 2013, 13, 150.	0.9	10
29	Good Practice Guidelines for the use of Statistical Regression Models in Economic Evaluations. Pharmacoeconomics, 2013, 31, 643-652.	1.7	21
30	Association between body mass index and health-related quality of life, and the impact of self-reported long-term conditions – cross-sectional study from the south Yorkshire cohort dataset. BMC Public Health, 2013, 13, 1009.	1.2	37
31	Aripiprazole for the Treatment and Prevention of Acute Manic and Mixed Episodes in BipolarÂl Disorder in Children and Adolescents: A NICE Single Technology Appraisal. Pharmacoeconomics, 2013, 31, 981-990.	1.7	9
32	Cabazitaxel for the Second-Line Treatment of Metastatic Hormone-Refractory Prostate Cancer: A NICE Single Technology Appraisal. Pharmacoeconomics, 2013, 31, 479-488.	1.7	29
33	Should There Be an Option to "Unrefer―Nice Single Technology Appraisals: Case Study of Aripiprazole for Bipolar I Disorder in Adolescents. Value in Health, 2013, 16, A615-A616.	0.1	0
34	Cost-effectiveness analysis of enhancements to angioplasty for infrainguinal arterial disease. British Journal of Surgery, 2013, 100, 1180-1188.	0.1	31
35	The Incidence and Costs of Adverse Events Associated with Antidepressants: Results from a Systematic Review, Network Meta-Analysis and Multi-Country Economic Model. Neuropsychiatric Disease and Treatment, 0, Volume 18, 1133-1143.	1.0	4